Spectrum Pharmaceuticals, Inc. Marketing Authorization Application for Satraplatin Accepted for Review by the European Medicines Evaluation Agency

IRVINE, Calif., July 27 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI - News) today announced that the Marketing Authorization Application (MAA) that was submitted to the European Medicines Agency (EMEA) by Pharmion Corporation (Nasdaq: PHRM - News) for satraplatin in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (HRPC) who have failed prior chemotherapy, has been accepted for review.